|Action Center - Six Classes|
In November 2018, the Centers for the Medicare and Medicaid Services (CMS) proposed a rule to make changes to the Six Protected Classes. While we applaud CMS’ efforts to lower drug prices, we recognize as pharmacists that the least expensive medication may not always be the best medication for the patient. Unwanted side effects that can lead to hospitalization and physician visits can add unneeded patient harm as well as costs to the health care system in areas outside of the cost of medications. Savings gained by restricting access to drugs in the Six Protected Classes will only shift the cost burden and lead to additional costs for patients, providers, and taxpayers.
In response to this proposal, ASCP and 75 of our members wrote a letter to the agency urging them to reconsider these life-threatening changes. The Society also partnered with NCPA and SCPC to write a letter that addresses our collective concerns regarding CMS’ Proposed Changes to Lower Drug Prices in Medicare Advantage and Part D.